Meeting
2024 ASCO Genitourinary Cancers Symposium
Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.
Authors
John Nikitas
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
John Nikitas , Ethan C. Lam , Kiara M Booker , Wolfgang P. Fendler , Matthias Eiber , Boris A. Hadaschik , Ken Herrmann , Nader Hirmas , Helena Lanzafame , Martin Stuschke , Johannes Czernin , Michael L. Steinberg , Nicholas George Nickols , Amar Upadhyaya Kishan , Jeremie Calais
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Clinical Trial Registration Number
NCT04457245
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 291)
DOI
10.1200/JCO.2024.42.4_suppl.291
Abstract #
291
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
First Author: Ryan Phillips
Poster
2023 ASCO Genitourinary Cancers Symposium
Detection of true positive M1 lesions by 18F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study.
First Author: Bridget F. Koontz
Poster
2022 ASCO Annual Meeting
Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.
First Author: Diogo Assed Bastos
Poster
2024 ASCO Genitourinary Cancers Symposium
Role of 18F-flotufolastat PET/CT imaging in men with high-risk prostate cancer following conventional imaging and associated changes in medical management: A phase 3b investigator-initiated trial.
First Author: Zachariah Taylor